Second Half Financial Partners LLC acquired a new stake in Amgen Inc. (NASDAQ:AMGN - Free Report) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 10,591 shares of the medical research company's stock, valued at approximately $3,413,000. Amgen comprises approximately 1.8% of Second Half Financial Partners LLC's investment portfolio, making the stock its 14th biggest position.
Other hedge funds have also recently added to or reduced their stakes in the company. Capital Performance Advisors LLP acquired a new position in shares of Amgen in the 3rd quarter valued at $25,000. Strategic Financial Concepts LLC acquired a new position in Amgen in the second quarter valued at about $26,000. Hershey Financial Advisers LLC bought a new stake in shares of Amgen in the second quarter worth about $30,000. nVerses Capital LLC acquired a new stake in shares of Amgen during the second quarter worth about $31,000. Finally, Bbjs Financial Advisors LLC bought a new position in shares of Amgen during the 2nd quarter valued at about $33,000. Institutional investors and hedge funds own 76.50% of the company's stock.
Analyst Upgrades and Downgrades
AMGN has been the subject of a number of research reports. Oppenheimer reissued an "outperform" rating and set a $380.00 target price on shares of Amgen in a research note on Wednesday, August 7th. Wolfe Research started coverage on shares of Amgen in a research report on Friday. They issued a "peer perform" rating on the stock. William Blair reiterated an "outperform" rating on shares of Amgen in a report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and set a $305.00 price objective (down from $310.00) on shares of Amgen in a research report on Wednesday, August 7th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $362.00 price target on shares of Amgen in a research report on Thursday, September 26th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $333.57.
Get Our Latest Stock Report on AMGN
Amgen Stock Performance
AMGN traded up $1.19 during trading hours on Tuesday, reaching $279.95. The company's stock had a trading volume of 3,210,343 shares, compared to its average volume of 2,459,217. The company's 50-day moving average is $319.90 and its 200-day moving average is $318.65. Amgen Inc. has a 52 week low of $260.52 and a 52 week high of $346.85. The firm has a market cap of $150.48 billion, a PE ratio of 35.69, a price-to-earnings-growth ratio of 2.53 and a beta of 0.60. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32.
Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, beating the consensus estimate of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The company had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. During the same period in the prior year, the firm earned $4.96 earnings per share. The company's revenue was up 23.2% on a year-over-year basis. On average, equities analysts forecast that Amgen Inc. will post 19.51 EPS for the current year.
Amgen Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Monday, December 9th. Stockholders of record on Monday, November 18th will be given a $2.25 dividend. This represents a $9.00 annualized dividend and a dividend yield of 3.21%. The ex-dividend date is Monday, November 18th. Amgen's payout ratio is 115.24%.
Amgen Profile
(
Free Report)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Further Reading
Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
